New York, NY -- (SBWIRE) -- 12/10/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Curis, Inc (NASDAQ:CRIS), E Commerce China Dangdang Inc (ADR) (NYSE:DANG), Pfizer Inc (NYSE:PFE), BAE Systems PLC (ADR) (OTCMKTS:BAESY)
Curis, Inc (NASDAQ:CRIS) showed a volume of 2.30 million shares by the end of last trade whereas the average volume of the stock remained 670,328.00 shares. The stock opened the session at $3.42 but then moved to $2.79. At that price, the stock showed a negative performance of -18.66%. Curis, Inc. is a drug discovery and development company that is committed to leveraging signaling pathway drug technologies in seeking to develop next generation network-targeted cancer therapies. The Company conducts its research and development programs both internally and through strategic collaborations. Its advanced program is Hedgehog pathway inhibitor program under collaboration with Genentech, Inc., a wholly owned member of the Roche Group. The lead drug candidate being developed under this program is Erivedge,
Will CRIS Get Buyers Even After The Recent Rally? Find Out Here
E Commerce China Dangdang Inc (ADR) (NYSE:DANG) opened the session at $9.09 and closed the session at $8.65. The stock showed a negative performance of -4.84% in previous trading session. Traded with volume of 2.52 million shares in the prior session and the average volume of the stock remained 2.32 million shares. E-Commerce China Dangdang Inc. (Dangdang) is a holding company. It is a business-to-consumer (B2C), e-commerce Company in the People’s Republic of China. As of September 30, 2010, it offered approximately 590,000 book titles on its Website, including more than 570,000 Chinese language titles. The Company also offers other media products and selected general merchandise categories on its Website, including beauty and personal care products,
Has DANG Found The Bottom And Ready To Gain Momentum? Find Out Here
Pfizer Inc (NYSE:PFE) opened the session at $31.53 and closed the session at $31.58. The stock showed a positive performance of 0.13% in previous trading session. Traded with volume of 21.26 million shares in the prior session and the average volume of the stock remained 23.96 million shares. The beta of the stock remained 0.84. Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. The Company manages its operations through five segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health, and Consumer Healthcare. The Company’s diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer healthcare products.
Why Should Investors Buy PFE After The Recent Gain? Just Go Here and Find Out
BAE Systems PLC (ADR) (OTCMKTS:BAESY) the stock decreased -0.11% and finished the session at $27.45. Traded with volume of 64,773.00 shares in the prior session and the average volume of the stock remained 108,051.00 shares. The beta of the stock remained 0.86. BAE Systems plc (BAE Systems) is a global defence, aerospace and security company. BAE Systems delivers, a range of products and services for air, land and naval forces, as well as advanced electronics, security, information technology solutions and support services. The Company operates in five segments: Electronic Systems consists of the United States- and United Kingdom-based electronics activities.
Will BAESY Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)